Biotech

All Articles

AstraZeneca posts information on in-house competitors to AbbVie, Pfizer ADCs

.AstraZeneca has actually discussed a very early look at the functionality of its internal antibody-...

iTeos- GSK's TIGIT superstar reveals meaningful enhancement

.After announcing a period 3 launch based upon good midstage results, iTeos and also GSK are actuall...

More collective FDA may increase rare condition R&ampD: record

.The FDA needs to be actually much more open as well as collaborative to discharge a rise in commend...

Zenas, MBX, Bicara head to Nasdaq in hot time for biotech IPOs

.It's an unusually busy Friday for biotech IPOs, with Zenas BioPharma, MBX and Bicara Rehabs all goi...

Atea's COVID antiviral falls short to halt hospital stays in period 3

.Atea Pharmaceuticals' antiviral has actually fallen short an additional COVID-19 test, however the ...

Neurocrine's bid to conserve mental illness prospect neglects

.Neurocrine Biosciences' mental illness program pivot has actually fallen short. The biotech was not...

Sanofi pays out $110M upfront for late-stage radioligand therapy

.Sanofi has actually made an overdue access to the radioligand event, paying one hundred million eur...

F 2G rears $100M for 2nd effort to obtain brand-new antifungal to market

.After F2G's first attempt to get a new class of antifungal to market was thwarted due to the FDA, t...

Moderna targets $1.1 B in R&ampD costs slices, drops 5 systems in the middle of earnings tensions

.Moderna has sworn to reduce R&ampD investing by $1.1 billion by 2027. The choice to shrink the fina...

Sanofi's $80M bet on Fulcrum dystrophy medicine finishes in stage 3 go bust

.Simply 4 months after Sanofi wager $80 thousand in beforehand cash on Key Therapies' losmapimod, th...